CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Quince Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Quince Therapeutics Inc
601 Gateway Boulevard, Suite 1250
Phone: (415) 910-5717p:415 910-5717 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: QNCXQNCX
Business Summary
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board David A.Lamond 49 2/1/2022 12/1/2015
President Charles S.Ryan 59 9/1/2023 9/1/2023
Chief Executive Officer, Chief Medical Officer, Director DirkThye 54 1/1/2024 5/20/2022
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Erydel S.p.A. Via Antonio Meucci, 3 Bresso Italy

Business Names
Business Name
Cortexyme Australia Pty Ltd
CORTEXYME INC
CRTX
9 additional Business Names available in full report.

General Information
Number of Employees: 32 (As of 12/31/2023)
Outstanding Shares: 44,001,643 (As of 11/5/2024)
Shareholders: 50
Stock Exchange: NASD
Federal Tax Id: 901024039
Fax Number: (302) 655-5049
Email Address: info@cortexyme.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024